Data Supplement
Files in this Data Supplement:
- Supplemental Data -
Supplemental Figure 1 - Immunoinhibition effect of anti-CYP3A4 antibody on metabolic activity of midazolam by liver microsomes of human
Supplemental Figure 2 - Plasma concentrations of CYP3A4 substrates of Alprazolam, Felodipine, Midazolam, Nifedipine, Nitrendipine, and Quinidine following an intravenous administration to CYP3A4 Tg-mice
Supplemental Figure 3 - Correlation estimated by linear regression analysis for the CLint,h of CYP3A4 substrates between CYP3A4-Tg mice and humans
Supplemental Figure 4 - Correlation for the CLint,h and FaFg of CYP3A4 substrates in humans
Supplemental Table 1-1 - The gradient conditions of HPLC eluent for measurement of drug conditions excepting for the plasma unbound fraction analysis
Supplemental Table 1-2 - The gradient conditions of HPLC eluent for measurement of drug conditions for the plasma unbound fraction analysis
Supplemental Table 2-1 - Mass number of the monitor ions for each compound for measurement of drug concentrations excepting for the plasma unbound fraction analysis
Supplemental Table 2-2 - Mass number of the monitor ions for each compound for measurement of drug concentrations for the plasma unbound fraction analysis
Supplemental Table 3 - Accuracy of the predicted human CLh of six CYP3A4 substrates based on the correlation of CLint,h between human and WT mice compared with observed values
Supplemental Table 4 - Pharmacokinetic parameters in human after oral administration